Dr. Katherine Coerver, MD
NPI: 1831161157
Total Payments
$40,557
2024 Payments
$10,467
Companies
67
Transactions
961
Medicare Patients
3,416
Medicare Billing
$528,053
Payment Breakdown by Category
Food & Beverage$18,932 (46.7%)
Other$14,313 (35.3%)
Consulting$4,410 (10.9%)
Travel$2,903 (7.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $18,932 | 939 | 46.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,678 | 4 | 21.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $5,635 | 3 | 13.9% |
| Consulting Fee | $4,410 | 2 | 10.9% |
| Travel and Lodging | $2,903 | 13 | 7.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $20,631 | 34 | $0 (2024) |
| ABBVIE INC. | $1,725 | 106 | $0 (2024) |
| GENZYME CORPORATION | $1,437 | 59 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $1,409 | 93 | $0 (2021) |
| UCB, Inc. | $1,178 | 51 | $0 (2024) |
| GE HEALTHCARE | $1,173 | 9 | $0 (2024) |
| Sage Therapeutics, Inc. | $1,123 | 8 | $0 (2023) |
| Amgen Inc. | $922.15 | 45 | $0 (2023) |
| Lundbeck LLC | $855.80 | 37 | $0 (2024) |
| Allergan, Inc. | $780.25 | 55 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,467 | 121 | Eisai Inc. ($8,154) |
| 2023 | $15,968 | 141 | Eisai Inc. ($12,453) |
| 2022 | $2,404 | 108 | ABBVIE INC. ($544.33) |
| 2021 | $2,493 | 76 | GE HEALTHCARE ($900.00) |
| 2020 | $2,054 | 110 | Allergan, Inc. ($281.30) |
| 2019 | $2,252 | 143 | Novartis Pharmaceuticals Corporation ($293.71) |
| 2018 | $2,834 | 137 | GENZYME CORPORATION ($379.57) |
| 2017 | $2,086 | 125 | Teva Pharmaceuticals USA, Inc. ($391.53) |
All Payment Transactions
961 individual payment records from CMS Open Payments — Page 1 of 39
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $12.82 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | Life Molecular Imaging Ltd | NEURACEQ (Drug) | Food and Beverage | Cash or cash equivalent | $12.97 | General |
| Category: Diagnostic Tracer | ||||||
| 12/16/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: EPILEPSY | ||||||
| 12/13/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: Neurology | ||||||
| 12/13/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $9.48 | General |
| Category: Neurology | ||||||
| 12/05/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $34.46 | General |
| Category: NEUROLOGY | ||||||
| 12/04/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $9.86 | General |
| Category: NEUROSCIENCE | ||||||
| 12/02/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $28.07 | General |
| 12/02/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $7.09 | General |
| Category: Neuropsychiatry | ||||||
| 11/25/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $7.49 | General |
| Category: Neurology | ||||||
| 11/22/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $33.11 | General |
| Category: Neurology | ||||||
| 11/22/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $19.01 | General |
| Category: PSYCHIATRY | ||||||
| 11/20/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $30.93 | General |
| Category: Neurology | ||||||
| 11/19/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $6.89 | General |
| Category: NEUROSCIENCE | ||||||
| 11/14/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $6.56 | General |
| Category: Neuropsychiatry | ||||||
| 11/12/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $30.79 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/07/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: Neuroscience | ||||||
| 11/06/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $9.09 | General |
| Category: NEUROSCIENCE | ||||||
| 11/05/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $41.24 | General |
| Category: Neurology | ||||||
| 10/31/2024 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $65.99 | General |
| 10/24/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $27.57 | General |
| Category: NEUROSCIENCE | ||||||
| 10/21/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $7.44 | General |
| Category: Neuropsychiatry | ||||||
| 10/18/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $6.72 | General |
| Category: Neurology | ||||||
| 10/16/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $75.62 | General |
| Category: Neuroscience | ||||||
| 10/15/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $20.03 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 826 | 1,117 | $385,175 | $137,640 |
| 2022 | 14 | 844 | 1,224 | $309,004 | $127,886 |
| 2021 | 17 | 1,038 | 1,576 | $426,812 | $165,269 |
| 2020 | 11 | 708 | 1,094 | $248,975 | $97,258 |
Total Patients
3,416
Total Services
5,011
Medicare Billing
$528,053
Procedure Codes
58
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2023 | 87 | 87 | $70,992 | $32,214 | 45.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 150 | 150 | $62,400 | $24,195 | 38.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 124 | 139 | $40,310 | $18,720 | 46.4% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | Office | 2023 | 60 | 64 | $46,912 | $13,234 | 28.2% |
| 96133 | Evaluation of neuropsychological test, each additional hour | Office | 2023 | 46 | 95 | $14,250 | $7,601 | 53.3% |
| 96137 | Administration of psychological or neuropsychological test, each additional 30 minutes | Office | 2023 | 46 | 231 | $23,100 | $6,764 | 29.3% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2023 | 45 | 45 | $12,105 | $6,380 | 52.7% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2023 | 46 | 46 | $11,040 | $4,862 | 44.0% |
| 95708 | Measurement of brain wave activity (eeg), 12-26 hours | Office | 2023 | 14 | 40 | $50,000 | $4,694 | 9.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $9,686 | $3,675 | 37.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 41 | 45 | $9,765 | $3,645 | 37.3% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 11 | 11 | $7,865 | $3,387 | 43.1% |
| 95700 | Measurement of brain wave activity (eeg), continuous | Office | 2023 | 14 | 14 | $11,200 | $2,727 | 24.3% |
| 95723 | Measurement of brain wave activity (eeg), 61-84 hours with health care professional review and report | Office | 2023 | 12 | 12 | $6,540 | $2,283 | 34.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 55 | 63 | $4,410 | $1,642 | 37.2% |
| 96136 | Administration of psychological or neuropsychological test, first 30 minutes | Office | 2023 | 46 | 46 | $4,600 | $1,616 | 35.1% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2022 | 74 | 74 | $60,384 | $27,387 | 45.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 119 | 119 | $49,504 | $19,288 | 39.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 108 | 126 | $36,540 | $17,286 | 47.3% |
| 96133 | Evaluation of neuropsychological test, each additional hour | Office | 2022 | 65 | 133 | $19,950 | $11,029 | 55.3% |
| 96137 | Administration of psychological or neuropsychological test, each additional 30 minutes | Office | 2022 | 65 | 323 | $32,300 | $10,340 | 32.0% |
| 99483 | Assessment of and care planning for impaired thought processing, typically 50 minutes | Office | 2022 | 47 | 52 | $38,116 | $10,252 | 26.9% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2022 | 65 | 65 | $17,485 | $9,393 | 53.7% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2022 | 65 | 65 | $15,600 | $6,970 | 44.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 71 | 82 | $17,794 | $6,830 | 38.4% |
About Dr. Katherine Coerver, MD
Dr. Katherine Coerver, MD is a Behavioral Neurology & Neuropsychiatry healthcare provider based in Centennial, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1831161157.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Katherine Coerver, MD has received a total of $40,557 in payments from pharmaceutical and medical device companies, with $10,467 received in 2024. These payments were reported across 961 transactions from 67 companies. The most common payment nature is "Food and Beverage" ($18,932).
As a Medicare-enrolled provider, Coerver has provided services to 3,416 Medicare beneficiaries, totaling 5,011 services with total Medicare billing of $528,053. Data is available for 4 years (2020–2023), covering 58 distinct procedure/service records.
Ad
Practice Information
- Specialty Behavioral Neurology & Neuropsychiatry
- Other Specialties Neurology
- Location Centennial, CO
- Active Since 02/02/2006
- Last Updated 02/04/2025
- Taxonomy Code 2084B0040X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1831161157
Products in Payments
- Leqembi (Drug) $20,486
- AUBAGIO (Drug) $1,205
- UBRELVY (Drug) $1,064
- VIZAMYL (Drug) $900.00
- Aimovig (Biological) $874.40
- INGREZZA (Drug) $659.81
- BOTOX (Biological) $647.51
- QULIPTA (Drug) $486.98
- Vimpat (Drug) $480.30
- VYEPTI (Biological) $436.71
- NURTEC ODT (Drug) $432.48
- MIGRANAL (Drug) $423.82
- AJOVY (Biological) $415.43
- EMGALITY (Drug) $403.88
- COPAXONE (Drug) $379.55
- NUPLAZID (Drug) $360.05
- AJOVY (Drug) $325.80
- REXULTI (Drug) $323.09
- RYTARY (Drug) $315.52
- GILENYA (Drug) $296.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.